Evidence map›Paper›PMID 35314347›Full record

ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2022

Safety, efficacy and delivery of multiple nucleoside analogs via drug encapsulated carbon (DECON) based sustained drug release platform.

Tejabhiram Yadavalli, Joshua Ames, David Wu, Benjamin Ramirez, Navya Bellamkonda, Deepak Shukla

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tejabhiram YadavalliDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago. 1905 West Taylor Street, Chicago, IL 60612, United States.
Joshua AmesDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago. 1905 West Taylor Street, Chicago, IL 60612, United States; Department of Microbiology and Immunology, University of Illinois at Chicago. 835 South Wolcott Avenue, Chicago, IL 60612, United States.
David WuDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago. 1905 West Taylor Street, Chicago, IL 60612, United States.
Benjamin RamirezNuclear Magnetic Resonance Core, Research Resources Center, University of Illinois at Chicago. 1100 South Ashland Avenue, Chicago, IL 60607, United States.
Navya BellamkondaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago. 1905 West Taylor Street, Chicago, IL 60612, United States.
Deepak ShuklaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago. 1905 West Taylor Street, Chicago, IL 60612, United States; Department of Microbiology and Immunology, University of Illinois at Chicago. 835 South Wolcott Avenue, Chicago, IL 60612, United States. Electronic address: dshukla@uic.edu.
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 1985 to 2025
$14.8M
A new molecular therapy against ocular herpesR01EY024710 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DEEPAK SHUKLA · 2015 to 2026
$5.2M
A small molecule inhibitor of HSV genital infectionsR01AI139768 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHUKLA, DEEPAK · 2018 to 2021
$1.6M
NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY024710NIAID NIH HHS R01 AI139768
6 · The paper itself

Abstract

Acyclovir and similar nucleoside analogs form an essential frontline treatment for various herpesvirus infections of the eye. However, these drugs have low ocular retention when delivered topically and need to be administered several times every day. We have previously demonstrated that acyclovir loaded into activated carbon can be used to significantly decrease dosage frequency in a murine model of ocular infection. In this study, we demonstrate that other nucleoside analogs such as ganciclovir, penciclovir and famciclovir have excellent loading and release profile similar to acyclovir. Similarly we also demonstrate that nucleoside analog loaded carbons termed DECON are effective at very low concentrations in treating active viral infection of human corneal epithelial cells. In this study, using a variety of techniques to evaluate corneal dryness, nerve sensitivity, intraocular pressure, corneal thickness, and somatic inflammation, we report that DECON is well tolerated after administration three times daily over the course of four weeks.

Indexed as

AcyclovirNucleosidesAnimalsAntiviral AgentsDrug LiberationHumansMiceAcyclovirAntiviral AgentsNucleosidesActivated carbonAcyclovirHerpes simplex virusNucleoside analogsOcular toxicityTopical delivery

Identifiers

PMID35314347
PMCPMC9113733
OpenAlexW4220742790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.